Leukemia

Justin Taylor, MD, spoke with Healio about a study he and colleagues conducted to examine mechanisms of resistance to noncovalent Bruton tyrosine kinase inhibitors.

Younger patients with acute lymphoblastic leukemia who do not respond to CD19-directed chimeric antigen receptor T-cell therapy exhibit certain gene regulation patterns that may be associated with treatment resistance, study results show.

CoVac-1, a COVID-19 vaccine, induced T-cell responses in patients with B-cell deficiencies, including those with lymphoma and leukemia, according to study results presented during American Association for Cancer Research Annual Meeting.

The FDA granted fast track designation to PRGN-3006 for the treatment of adults with relapsed or refractory acute myeloid leukemia.

Commercially available chimeric antigen receptor T cells for acute myeloid leukemia could be just a few years away, according to a presenter at the inaugural Personalizing Pediatric Cancer Care Summit.

B-cell activating factor is a ligand protein, which makes it uniquely suited as a therapeutic option for the newly emerging class of multitargeted chimeric antigen receptor T-cell therapies.

The FDA granted orphan drug designation to WU-CART-007 for patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

The FDA granted orphan drug designation to TCB-002 for treatment of adults with relapsed or refractory acute myeloid leukemia.

The FDA granted orphan drug designation to NTLA-5001 for treatment of adults with relapsed or refractory acute myeloid leukemia.

The FDA granted priority review to ivosidenib tablets in combination with azacitidine for previously untreated IDH1-mutated acute myeloid leukemia.